With a percutaneous femoral approach, iVAC2L can support with a pulsatile flow patients with impaired left ventricular function who require a mechanical circulatory support as bridge to decision or bridge to bridge (left ventricle assist device).1The use of the iVAC2L is found to be effective in high risk percutaneous coronary intervention (PCI) procedures.2
The catheter is composed of an inlet tip, an integrated bi-directional valve and a connector for connection to the membrane pump.
The mechanism of the iVAC2L is a patented bi-directional valve integrated in a 17 Fr single lumen and 100 cm long catheter. This catheter is connected to an extracorporeal 40 ml membrane pump. It is compatible with a standard IABP console and does not require dedicated hardware.
During the systolic phase of the heart, up to 1.5 l/min of blood is aspirated through the tip of the catheter from the left ventricle into the membrane pump.
During the diastolic phase of the heart, the bi-directional valve changes position blocking the via to the left ventricle and the blood can be given back directly into the ascending aorta (the aortic valve is closed)
The pulsatile synchronization ensures that the cardiac output is not impaired but enhanced.
iVAC2L is a trademark of PulseCath b.v., The Netherlands
iVAC2L is manufactured by PulseCath b.v. and exclusively distributed by Terumo Europe NV in the following countries: France, Germany, Austria, Switzerland, Italy, Spain, Netherlands, Belgium.
1 Use of the device approved for up to 24h according to IFU of the iVAC2L product.2 Application of a Pulsatile Catheter Pump in Left Ventricle Cardiac Assistance for up to 24 hours in high risk PCI Patients; An interim Clinical investigation Report; PulseCath October 2014.